Gastric ulcer Medical Services in China

A gastric ulcer is a circumscribed mucosal defect in the stomach lining that extends through the muscularis mucosae into the submucosa or deeper layers. Unlike superficial erosions, gastric ulcers involve structural disruption of the gastric wall and carry higher risks of complications including bleeding, perforation, gastric outlet obstruction, and malignant transformation. Pathogenesis centers on an imbalance between aggressive factors—primarily Helicobacter pylori infection (present in 70–90% of cases), nonsteroidal anti-inflammatory drug (NSAID) use, excessive gastric acid secretion, and smoking—and defensive mechanisms such as mucus-bicarbonate barrier integrity, mucosal blood flow, prostaglandin synthesis, and epithelial restitution. H. pylori induces chronic active gastritis, disrupts tight junctions, increases IL-8-mediated neutrophil infiltration, and upregulates acid production via ghrelin and histamine pathways. NSAIDs inhibit cyclooxygenase-1 (COX-1), reducing protective prostaglandins (PGE2 and PGI2) critical for mucus secretion and microvascular perfusion. Epidemiologically, gastric ulcers affect approximately 5–10% of the global population during their lifetime, with incidence rising sharply after age 50. In China, prevalence is estimated at 4.5–6.2% among adults undergoing upper endoscopy for dyspepsia, with male-to-female ratio of ~1.8:1. Key modifiable risk factors include chronic NSAID or low-dose aspirin use, smoking (doubles ulcer risk and impairs healing), heavy alcohol consumption, psychological stress (via vagal hyperactivity and impaired mucosal defense), and untreated H. pylori infection. Non-modifiable risks include advanced age, prior peptic ulcer disease, and genetic polymorphisms affecting interleukin-1β and TNF-α expression. Gastric ulcers significantly impair quality of life: patients commonly report recurrent epigastric pain (often burning or gnawing, worsened by fasting and relieved by food/antacids), early satiety, nausea, postprandial bloating, and fear of eating—leading to weight loss, sleep disruption, work absenteeism, and heightened anxiety about malignancy. Untreated or recurrent ulcers correlate with reduced physical functioning scores (SF-36), increased depression prevalence (up to 32%), and diminished social participation. With timely diagnosis—typically via esophagogastroduodenoscopy (EGD) with biopsy—and evidence-based therapy, >90% of uncomplicated ulcers heal within 6–8 weeks, and recurrence rates drop below 10% with sustained H. pylori eradication and NSAID de-escalation.

Gastric ulcers—defined as discrete mucosal breaks in the stomach lining extending through the muscularis mucosae—are primarily driven by an imbalance between aggressive luminal factors and the gastric mucosal defense mechanisms. The most common cause is chronic infection with Helicobacter pylori, a gram-negative, microaerophilic bacterium that colonizes the gastric epithelium. H. pylori induces inflammation via virulence factors (e.g., CagA, VacA), disrupts tight junctions, suppresses acid-inhibitory somatostatin signaling, and stimulates gastrin release—leading to both localized mucosal injury and, in some cases, paradoxical hyperchlorhydria. Eradication of H. pylori results in ulcer healing in >90% of cases and dramatically reduces recurrence rates.

Nonsteroidal anti-inflammatory drugs (NSAIDs) constitute the second leading cause. NSAIDs inhibit cyclooxygenase-1 (COX-1), diminishing prostaglandin E2 (PGE2) synthesis—a critical mediator of mucus secretion, bicarbonate production, mucosal blood flow, and epithelial restitution. This compromises mucosal integrity, rendering the stomach vulnerable to autodigestion by pepsin and gastric acid. Selective COX-2 inhibitors confer lower—but not absent—gastric risk, particularly when co-administered with low-dose aspirin or in elderly patients. Other pharmacologic triggers include corticosteroids (especially when combined with NSAIDs), bisphosphonates (e.g., alendronate), potassium chloride tablets, and selective serotonin reuptake inhibitors (SSRIs), which may impair platelet function and microvascular perfusion.

Physiologic and behavioral risk factors significantly modulate susceptibility. Cigarette smoking impairs mucosal blood flow, delays ulcer healing, increases gastric acid output, and reduces prostaglandin synthesis and epidermal growth factor expression. Heavy alcohol consumption (>40 g/day) directly damages surface epithelial cells, disrupts the mucus-bicarbonate barrier, and promotes oxidative stress and neutrophil infiltration. Psychological stress—while not causative in isolation—exacerbates ulcer formation in predisposed individuals by augmenting sympathetic tone, reducing gastric mucosal perfusion, stimulating vagally mediated acid secretion, and impairing mucosal repair pathways. Sleep deprivation and circadian disruption further dysregulate ghrelin, leptin, and cortisol rhythms, indirectly influencing gastric motility and barrier function.

Genetic factors contribute modestly but meaningfully to interindividual variability. Polymorphisms in interleukin-1β (IL-1B) and interleukin-1 receptor antagonist (IL-1RN) genes are associated with heightened proinflammatory responses to H. pylori and increased risk of hypochlorhydria, atrophic gastritis, and subsequent ulceration. TNF-α promoter variants (e.g., -308 G>A) correlate with more severe gastric inflammation. Additionally, polymorphisms in genes encoding drug-metabolizing enzymes—including CYP2C9 (involved in NSAID metabolism) and GSTM1 (glutathione S-transferase mu-1, involved in detoxifying reactive oxygen species)—modify individual vulnerability to NSAID-induced injury and oxidative mucosal damage.

Environmental determinants encompass socioeconomic, geographic, and lifestyle domains. Lower socioeconomic status correlates with higher H. pylori seroprevalence due to crowded living conditions and limited sanitation infrastructure during childhood—the critical window for acquisition. Urban-rural disparities persist globally, with rural populations exhibiting earlier and more prevalent H. pylori colonization. Occupational exposures—including chronic shift work, high-demand service occupations, and exposure to industrial solvents—may amplify systemic inflammation and autonomic dysregulation. Dietary patterns also play a role: diets low in antioxidants (vitamins A, C, E, selenium), fiber, and polyphenols—and high in salt, processed meats, and nitrates—promote gastric inflammation, oxidative DNA damage, and H. pylori virulence expression. Conversely, diets rich in cruciferous vegetables (sulforaphane), fermented dairy (Lactobacillus strains), and omega-3 fatty acids demonstrate protective associations in epidemiologic studies. Finally, advancing age (>60 years) independently increases risk due to diminished mucosal regenerative capacity, reduced salivary and gastric bicarbonate secretion, and higher prevalence of comorbidities requiring polypharmacy—including anticoagulants and antiplatelets that compound bleeding risk in established ulcers.

Gastric ulcers—circumscribed mucosal defects extending through the muscularis mucosae into the submucosa of the stomach—are a common pathology encountered in gastroenterology. They arise predominantly from an imbalance between aggressive luminal factors (e.g., gastric acid, pepsin, Helicobacter pylori infection, NSAID use) and defensive mucosal mechanisms (e.g., mucus-bicarbonate barrier, epithelial restitution, prostaglandin-mediated cytoprotection). Clinical presentation varies widely, ranging from asymptomatic incidental findings to life-threatening complications.

Early symptoms are often subtle and nonspecific, frequently overlooked or attributed to functional dyspepsia. Patients may report intermittent epigastric discomfort described as a dull, burning, or gnawing sensation, typically occurring 30–60 minutes after meals—distinct from duodenal ulcer pain, which usually improves with food and worsens during fasting. Early satiety, mild postprandial bloating, and transient nausea may occur without vomiting. Some individuals experience mild anorexia or aversion to spicy or acidic foods. Importantly, up to 20–30% of patients with endoscopically confirmed gastric ulcers are entirely asymptomatic at initial presentation, especially those on chronic NSAIDs or low-dose aspirin, or elderly patients with blunted symptom perception.

Typical symptoms reflect localized mucosal injury and inflammatory response. The hallmark is recurrent, centrally located epigastric pain—often rhythmic but less predictable than in duodenal ulcers. Pain intensity may fluctuate over days to weeks and is commonly exacerbated by gastric distension (e.g., large meals), alcohol, caffeine, or NSAIDs. It is rarely relieved by antacids or H2-receptor antagonists for more than 1–2 hours, distinguishing it from milder functional dyspepsia. Hematemesis (vomiting of bright red blood or coffee-ground material) and melena (black, tarry stools) represent overt gastrointestinal bleeding and signify ulcer penetration into submucosal vessels; these are not early features but rather indicators of active or recent hemorrhage. In contrast, occult blood loss may manifest insidiously as fatigue, pallor, exertional dyspnea, or unexplained iron-deficiency anemia—particularly in older adults or women of childbearing age.

Accompanying symptoms include anorexia, unintentional weight loss (a red-flag feature warranting urgent evaluation), and persistent nausea. Vomiting occurs in approximately 15–25% of cases, especially when ulcers are proximal (fundic or cardial) or associated with gastric outlet obstruction. Dyspeptic symptoms such as belching, regurgitation, or sour taste may coexist but are not diagnostic. Systemic signs like low-grade fever or malaise are uncommon unless complicated by perforation or severe hemorrhage. Notably, H. pylori infection may contribute additional constitutional symptoms—including halitosis, oral mucosal changes, or chronic halitosis—but these lack specificity.

Complications significantly influence morbidity and mortality. Upper gastrointestinal bleeding is the most frequent complication (occurring in ~40% of hospitalized ulcer patients), presenting with hematemesis, melena, orthostatic hypotension, tachycardia, or syncope. Perforation—full-thickness breach of the gastric wall—results in acute peritonitis: sudden, severe, knife-like epigastric pain radiating to the shoulders (referred via phrenic nerve irritation), rigid abdomen, rebound tenderness, and absent bowel sounds. Radiographic evidence of free intraperitoneal air on upright chest or abdominal X-ray confirms diagnosis. Gastric outlet obstruction (GOO), though less common (<5%), arises from chronic scarring and edema near the pylorus or antrum, causing progressive postprandial vomiting (often voluminous and containing undigested food), early satiety, visible gastric peristalsis, and hypochloremic, hypokalemic metabolic alkalosis. Malignant transformation remains a critical concern: while most gastric ulcers are benign, persistent or enlarging ulcers—especially in the gastric body or fundus—carry a 2–5% risk of underlying adenocarcinoma. Ulcer-associated gastric cancer may mimic benign ulcer clinically, underscoring the necessity of rigorous histopathologic evaluation.

Diagnosis relies on a multimodal approach. Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) remains the gold standard: it permits direct visualization, precise localization, assessment of size/shape/margins (e.g., irregular, raised, or heaped-up borders raise suspicion for malignancy), and targeted biopsies. Biopsy specimens should be obtained from ulcer margins and base (minimum 6–8 samples) to exclude malignancy and test for H. pylori (via rapid urease test, histology, or culture). Non-invasive H. pylori testing—including urea breath test, stool antigen assay, or serology (less preferred due to inability to distinguish past vs. current infection)—is indicated pre- and post-eradication. Serum gastrin levels should be measured if Zollinger-Ellison syndrome is suspected (e.g., multiple ulcers, refractory disease, diarrhea, hypersecretion). Contrast-enhanced CT may detect complications (e.g., perforation, abscess) but lacks sensitivity for primary ulcer detection. Barium upper GI series has largely been supplanted by endoscopy but may reveal a discrete mucosal niche or deformity in non-cooperative patients.

Differential diagnosis is essential to avoid mismanagement. Functional dyspepsia shares overlapping symptoms (epigastric pain, bloating, early satiety) but lacks objective mucosal injury on endoscopy and shows no alarm features. Gastroesophageal reflux disease (GERD) typically presents with retrosternal heartburn and regurgitation, often positional and responsive to PPIs; however, concomitant gastric ulcers may coexist. Gastric malignancy must always be excluded—ulcerated adenocarcinoma may mimic benign ulcer endoscopically, particularly if solitary, large (>2 cm), or in atypical locations. Other considerations include gastric lymphoma (often associated with H. pylori, presenting with large, shallow ulcers), Crohn’s disease (rare gastric involvement, often with skip lesions and concurrent intestinal disease), eosinophilic gastroenteritis (peripheral eosinophilia, mucosal edema), and infectious ulcers (e.g., CMV in immunocompromised hosts, tuberculosis, syphilis). Medication-induced injury (e.g., bisphosphonates, potassium chloride tablets) may cause linear or kissing ulcers, typically in the esophagus but occasionally in the gastric cardia. Finally, ischemic gastropathy—seen in critically ill or vasculopathic patients—may present with acute ulceration and bleeding, often multifocal and associated with systemic hypoperfusion markers.

In summary, gastric ulcer symptomatology spans a broad spectrum—from silent mucosal injury to catastrophic hemorrhage or perforation. Recognition of alarm features (weight loss, anemia, vomiting, age >55 at first presentation, family history of gastric cancer), timely endoscopic evaluation, meticulous biopsy strategy, and systematic exclusion of mimics are indispensable for accurate diagnosis, appropriate therapy, and prevention of adverse outcomes.

Gastric ulcers—circumscribed mucosal defects extending through the muscularis mucosae into the gastric submucosa—are a common yet potentially serious manifestation of gastroduodenal pathology. Management in gastroenterology departments prioritizes ulcer healing, symptom relief, complication prevention (e.g., hemorrhage, perforation, obstruction, or malignancy), and eradication of underlying etiologies—most notably Helicobacter pylori infection and nonsteroidal anti-inflammatory drug (NSAID) use. Treatment is stratified into conservative (non-invasive), pharmacologic, and surgical modalities, with individualized decision-making guided by endoscopic findings, patient comorbidities, ulcer size and location, bleeding stigmata, and response to initial therapy.

Conservative treatment forms the cornerstone for most uncomplicated gastric ulcers and emphasizes lifestyle modification and risk factor mitigation. Patients are advised to discontinue all NSAIDs—including low-dose aspirin—unless clinically indispensable (e.g., secondary cardiovascular prevention), in which case gastroprotection with proton pump inhibitors (PPIs) must be co-administered. Smoking cessation is strongly mandated, as nicotine impairs mucosal blood flow, reduces bicarbonate secretion, and delays ulcer healing. Alcohol intake should be restricted or eliminated due to its direct mucosal irritant effect and synergistic interaction with H. pylori and NSAIDs. Dietary counseling focuses on symptom-guided adjustments rather than rigid restrictions; while spicy, acidic, or caffeinated foods do not cause ulcers, they may exacerbate dyspepsia in sensitive individuals. Stress reduction techniques—including cognitive behavioral therapy and mindfulness-based interventions—are recommended adjunctively, particularly in patients with functional dyspepsia overlapping with ulcer symptoms, though psychosocial stress alone is not a primary ulcerogenic factor.

Pharmacotherapy remains the mainstay of medical management. First-line treatment centers on high-dose PPIs (e.g., esomeprazole 40 mg once daily or rabeprazole 20 mg twice daily) administered for 8 weeks to achieve optimal acid suppression (intragastric pH > 4 for ≥16 hours/day), which promotes mucosal restitution and inhibits pepsin activity. For H. pylori-positive ulcers—which account for approximately 70–80% of idiopathic cases—concomitant eradication therapy is mandatory. Current Chinese and international guidelines endorse bismuth quadruple therapy as first-line: a PPI plus bismuth subsalicylate (240 mg twice daily), tetracycline (500 mg four times daily), and metronidazole (400 mg four times daily) for 10–14 days. This regimen achieves >90% eradication rates in China, where clarithromycin resistance exceeds 25%, rendering standard triple therapy obsolete. In penicillin-allergic patients, high-dose dual therapy (PPI + amoxicillin 1 g three times daily) is an emerging alternative supported by recent multicenter trials in China. For NSAID-induced ulcers without H. pylori, PPI continuation beyond acute healing (typically 6 months) is indicated if NSAID rechallenge is unavoidable. Misoprostol (a prostaglandin E1 analog) may be considered in select high-risk patients intolerant to PPIs, though its side-effect profile (diarrhea, uterine cramping) limits adherence.

Surgical intervention is now rare (<1% of cases) but remains critical for life-threatening complications. Indications include hemodynamically unstable upper gastrointestinal bleeding refractory to endoscopic hemostasis (e.g., visible vessel, spurting), free perforation with peritonitis, gastric outlet obstruction unresponsive to medical decompression and dilation, or suspicion of malignancy on biopsy or imaging. Laparoscopic wedge resection or partial gastrectomy (Billroth I or II) is preferred over open surgery, offering reduced postoperative pain, shorter hospital stays (median 4–6 days), and faster return to oral intake. In China, robotic-assisted gastrectomy is increasingly performed in tertiary centers for complex or recurrent ulcers, leveraging enhanced dexterity and 3D visualization. Surgery also plays a diagnostic role when endoscopic biopsies are inconclusive but clinical suspicion for gastric adenocarcinoma remains high—particularly in ulcers >2 cm, irregular margins, or those failing to heal after 12 weeks of optimized medical therapy.

Treatment advantages in China stem from integrated, protocol-driven care across tiered healthcare institutions. National consensus guidelines (e.g., the 2023 Chinese Society of Gastroenterology Ulcer Management Recommendations) standardize H. pylori testing (stool antigen, urea breath test, or rapid urease test during endoscopy) and empiric regimens based on local resistance patterns. High-volume endoscopy centers perform >500 therapeutic upper GI endoscopies annually, ensuring expertise in advanced hemostatic techniques (e.g., hemoclip placement, epinephrine injection with thermal coagulation). Real-time tele-endoscopy networks connect rural hospitals with provincial experts for urgent second opinions. Moreover, China’s national essential medicines list ensures universal access to generic PPIs and bismuth compounds at minimal cost, improving adherence. Pharmacovigilance systems monitor regional antibiotic resistance trends, enabling dynamic regimen updates—contributing to sustained >90% eradication success in compliant patients.

Recovery advice emphasizes structured follow-up and long-term vigilance. All patients require repeat upper endoscopy at 8–12 weeks post-treatment to confirm complete healing and exclude malignancy—mandatory even in H. pylori-negative or NSAID-related ulcers. H. pylori eradication must be confirmed via urea breath test or stool antigen test ≥4 weeks after therapy completion and off PPIs for ≥2 weeks. Patients should avoid NSAIDs for at least 8 weeks post-healing; if reinstitution is necessary, concurrent PPI prophylaxis is non-negotiable. Annual symptom review is advised for those with recurrent ulcer history or chronic NSAID use. Nutritional support includes small, frequent meals rich in zinc, vitamin A, and antioxidants (e.g., berries, leafy greens), which support epithelial repair. Finally, patients must recognize red-flag symptoms—hematemesis, melena, persistent vomiting, or unrelenting epigastric pain—and seek immediate evaluation, as delayed presentation increases mortality in complicated disease. With comprehensive, evidence-based, and accessible care, gastric ulcer prognosis in modern gastroenterology practice is excellent, with >95% healing rates and <2% recurrence at one year when risk factors are adequately controlled.